Where I see patients (1)
Selected research
-
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression.
Nature communications
-
Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits.
JNCI cancer spectrum
-
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4.
Cell reports